Here are the available video segments and related powerpoint presentations:
- last 1/3 of opening talk by Rick Doblin, Ph.D., then Dr. Michael Mithoefer (This one starts a bit jumpy but it gets better fairly soon)
- Dr. Michael Mithoefer
- continuation of Dr. Michael Mithoefer
- See J.C Bouso’s powerpoint presentation.
- continuation of June May Ruse, Ph.D.
- Valerie Mojeiko and her powerpoint presentation
- continuation of Valerie Mojeiko, then Dr. Udi Bastiaans
- continuation of Dr. Udi Bastiaans, then Dr. John Halpern
- continuation of Dr. John Halpern
- continuation of Dr. John Halpern
- Jordi Riba, Ph.D.
- continuation of Jordi Riba, Ph.D., then Dr. Torsten Passie
MAPS conference in Israel. MAPS sponsored a one-day scientific conference in Israel, in conjunction with the Israeli Ministry of Health and the Society of Addiction Medicine, in support of the proposed MDMA/PTSD study. After the conference, the study’s primary investigator, Dr. Moshe Kotler, submitted the study protocol.
Speakers, in order of presentation, were:
- Rick Doblin, Ph.D., MAPS President
- Michael Mithoefer, M.D., primary investigator for the U.S. MAPS-sponsored MDMA/PTSD study
- Raphael Mechoulam, Ph.D., Israeli cannabis researcher who discovered THC and the endocannabinoid system
- Jose Carlos Bouso, Ph.D. Candidate, primary investigator for the proposed MAPS-sponsored MDMA/PTSD study in Spain
- June May Ruse, Ph.D., director of the MDMA/PTSD Treatment Manual project
- Valerie Mojeiko, MAPS Clinical Research Associate coordinating the outcome study on ibogaine for substance abuse
- Udi Bastiaans, M.D., Israeli doctor researching ibogaine treatment
- John Halpern, M.D., primary investigator for the MAPS-sponsored study of MDMA-assisted psychotherapy for anxiety in cancer patients, to be conducted at Harvard Medical School’s McLean Hospital
- Jordi Riba, Ph.D., Spanish pharmacologist researching ayahuasca
- Torsten Passie, M.D., German psilocybin researcher
